{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:04Z","timestamp":1791489664080,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["53232267"],"award-info":[{"award-number":["53232267"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/aim<\/jats:title>\n                <jats:p>Despite optimal conventional treatment (oral phosphate supplements and active vitamin D analogs), about 40\u201350% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, making them less likely to achieve an acceptable final height. Here, we studied the hypothesis that rhGH treatment improves final height in children with XLH and growth failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two cohorts of children with XLH were included in this retrospective longitudinal analysis: (1) a cohort treated with rhGH for short stature (n\u2009=\u200934) and (2) a cohort not treated with rhGH (n\u2009=\u200929). The mean duration of rhGH treatment was 4.4\u2009\u00b1\u20092.9\u00a0years. We collected the auxological parameters at various time points during follow-up until final height.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In rhGH-treated children, 2\u00a0years of rhGH therapy was associated with a significant increase in height from \u2212\u20092.4\u2009\u00b1\u20090.9 to \u2212\u20091.5\u2009\u00b1\u20090.7 SDS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Their mean height at rhGH discontinuation was \u2212\u20091.2\u2009\u00b1\u20090.9 SDS and at final height was \u2212\u20091.3\u2009\u00b1\u20090.9 SDS corresponding to 165.5\u2009\u00b1\u20096.4\u00a0cm in boys and 155.5\u2009\u00b1\u20096.3\u00a0cm in girls. Notably, the two groups had similar final heights; i.e., the final height in children not treated with rhGH being \u2212\u20091.2\u2009\u00b1\u20091.1 SDS (165.4\u2009\u00b1\u20096.8\u00a0cm in boys and 153.7\u2009\u00b1\u20097.8\u00a0cm in girls), <jats:italic>p<\/jats:italic>\u2009=\u20090.7.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Treatment with rhGH permits to improve final height in children with XLH and growth failure, despite optimal conventional treatment. We propose therefore that rhGH therapy could be considered as an option for short stature in the context of XLH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02590-5","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T12:02:57Z","timestamp":1671624177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Growth hormone treatment improves final height in children with X-linked hypophosphatemia"],"prefix":"10.1186","volume":"17","author":[{"given":"Julia","family":"Andr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-1855","authenticated-orcid":false,"given":"Volha V.","family":"Zhukouskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"2590_CR1","unstructured":"Ruppe MD. X-linked hypophosphatemia. Gene Rev. 2017; 22."},{"key":"2590_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"F Francis","year":"1995","unstructured":"Francis F. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet. 1995;11:130\u20136.","journal-title":"Nat Genet"},{"issue":"5","key":"2590_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2005111185","volume":"17","author":"S Liu","year":"2006","unstructured":"Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. JASN. 2006;17(5):1305\u201315.","journal-title":"JASN"},{"issue":"7","key":"2590_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435\u201355.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"2590_CR5","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","volume":"88","author":"O M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88(8):3591\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"2590_CR6","first-page":"119","volume":"17","author":"M Cagnoli","year":"2017","unstructured":"Cagnoli M. Spontaneous growth and effect of early therapy with calcitriol and phosphate in X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev. 2017;17:119\u201322.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"6","key":"2590_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/BF01959355","volume":"151","author":"R Steendijk","year":"1992","unstructured":"Steendijk R, Hauspie RC. The pattern of growth and growth retardation of patients with hypophosphataemic vitamin D-resistant rickets: a longitudinal study. Eur J Pediatr. 1992;151(6):422\u20137.","journal-title":"Eur J Pediatr"},{"issue":"8668","key":"2590_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0140-6736(89)91559-6","volume":"334","author":"S GunnarB","year":"1989","unstructured":"GunnarB S, BruceZ M. Hypophosphatemic rickets: final height and clinical symptoms in adults. Lancet. 1989;334(8668):902\u20135.","journal-title":"Lancet"},{"issue":"3","key":"2590_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000045518","volume":"83","author":"D Haffner","year":"1999","unstructured":"Haffner D, Weinfurth A, Manz F, Schmidt H, Bremer HJ, Mehls O, et al. Long-term outcome of paediatric patients with hereditary tubular disorders. Nephron. 1999;83(3):250\u201360.","journal-title":"Nephron"},{"issue":"1","key":"2590_CR10","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13-30.","journal-title":"Endocr Connect"},{"issue":"12","key":"2590_CR11","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1210\/jc.2007-2553","volume":"93","author":"F Jehan","year":"2008","unstructured":"Jehan F, Gaucher C, Nguyen TM, Walrant-Debray O, Lahlou N, Sinding C, et al. Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment. J Clin Endocrinol Metab. 2008;93(12):4672\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2590_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0022-3476(05)82822-7","volume":"116","author":"S Balsan","year":"1990","unstructured":"Balsan S, Tieder M. Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: Influence of treatment regimen and parental height. J Pediatr. 1990;116(3):365\u201371.","journal-title":"J Pediatr"},{"key":"2590_CR13","doi-asserted-by":"crossref","unstructured":"Reusz GS. Hypophosphataemic rickets. The Lancet. 1990; 178","DOI":"10.1016\/0140-6736(90)90058-D"},{"key":"2590_CR14","first-page":"33","volume":"45","author":"M Berndt","year":"1996","unstructured":"Berndt M. Clinical course of hypophosphatemic rickets in 23 adults. Clin Nephrol. 1996;45:33\u201341.","journal-title":"Clin Nephrol"},{"key":"2590_CR15","doi-asserted-by":"crossref","unstructured":"Yakar S. Insulin-like growth factors: actions 1 on the skeleton. J Mol Endocrinol 2018; 17\u20110298.","DOI":"10.1530\/JME-17-0298"},{"issue":"5","key":"2590_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1542\/peds.100.5.879","volume":"100","author":"MG Seikaly","year":"1997","unstructured":"Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics. 1997;100(5):879\u201384.","journal-title":"Pediatrics"},{"issue":"12","key":"2590_CR17","doi-asserted-by":"publisher","first-page":"E2097","DOI":"10.1210\/jc.2011-0399","volume":"96","author":"M \u017divi\u010dnjak","year":"2011","unstructured":"\u017divi\u010dnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab. 2011;96(12):E2097\u2013105.","journal-title":"J Clin Endocrinol Metab"},{"key":"2590_CR18","doi-asserted-by":"crossref","unstructured":"On Behalf of the Hypophosphatemic Rickets Study Group of the \u201cDeutsche Gesellschaft f\u00fcr Kinderendokrinologie und -diabetologie\u201d and \u201cGesellschaft f\u00fcr P\u00e4diatrische Nephrologie\u201d, Meyerhoff N, Haffner D, Staude H, W\u00fchl E, Marx M, et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 2018;33(3):447\u201156.","DOI":"10.1007\/s00467-017-3820-3"},{"issue":"5","key":"2590_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s004670050340","volume":"11","author":"GS Reusz","year":"1997","unstructured":"Reusz GS, Milt\u00e9nyi G, Stubnya G, Szab\u00f3 A, Horv\u00e1th C, Byrd DJ, et al. X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol. 1997;11(5):573\u20137.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2590_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0022-3476(95)70070-6","volume":"127","author":"G Saggese","year":"1995","unstructured":"Saggese G, Baroncelli GI, Bertelloni S, Perri G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J Pediatr. 1995;127(3):395\u2013402.","journal-title":"J Pediatr"},{"key":"2590_CR21","unstructured":"Hammerman MR. The growth hormone-insulin-like growth factor axis in kidney. 12"},{"issue":"4","key":"2590_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000113021","volume":"69","author":"O M\u00e4kitie","year":"2008","unstructured":"M\u00e4kitie O, Toiviainen-Salo S, Marttinen E, Kaitila I, Sochett E, Sipil\u00e4 I. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets. Horm Res Paediatr. 2008;69(4):212\u201320.","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"2590_CR23","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1210\/jc.2009-2531","volume":"95","author":"A Rothenb\u00fchler","year":"2010","unstructured":"Rothenb\u00fchler A, Piquard C, Gueorguieva I, Lahlou N, Linglart A, Bougn\u00e8res P. Near normalization of adult height and body proportions by growth hormone in pycnodysostosis. J Clin Endocrinol Metab. 2010;95(6):2827\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"2590_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ghir.2017.08.001","volume":"36","author":"A Rothenbuhler","year":"2017","unstructured":"Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M, et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Hormon IGF Res. 2017;36:11\u20135.","journal-title":"Growth Hormon IGF Res"},{"issue":"2","key":"2590_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1067\/mpd.2001.108955","volume":"138","author":"GI Baroncelli","year":"2001","unstructured":"Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr. 2001;138(2):236\u201343.","journal-title":"J Pediatr"},{"issue":"1","key":"2590_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11154-017-9408-1","volume":"18","author":"R Fuente","year":"2017","unstructured":"Fuente R, Gil-Pe\u00f1a H, Claramunt-Taberner D, Hern\u00e1ndez O, Fern\u00e1ndez-Iglesias A, Alonso-Dur\u00e1n L, et al. X-linked hypophosphatemia and growth. Rev Endocr Metab Disord. 2017;18(1):107\u201315.","journal-title":"Rev Endocr Metab Disord"},{"key":"2590_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1530\/eje.0.1490317","volume":"149","author":"S Schutt","year":"2003","unstructured":"Schutt S, Schumacher M, Holterhus P, Felgenhauer S, Hiort O. Effect of GH replacement therapy in two male siblings with combined X-linked hypophosphatemia and partial GH deficiency. Eur J Endocrinol. 2003;149:317\u201321.","journal-title":"Eur J Endocrinol"},{"key":"2590_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bone.2018.08.004","volume":"116","author":"R Fuente","year":"2018","unstructured":"Fuente R, Gil-Pe\u00f1a H, Claramunt-Taberner D, Hern\u00e1ndez-Fr\u00edas O, Fern\u00e1ndez-Iglesias \u00c1, Hermida-Prado F, et al. Marked alterations in the structure, dynamics and maturation of growth plate likely explain growth retardation and bone deformities of young Hyp mice. Bone. 2018;116:187\u201395.","journal-title":"Bone"},{"issue":"10","key":"2590_CR29","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1210\/en.2014-1315","volume":"155","author":"ES Liu","year":"2014","unstructured":"Liu ES, Zalutskaya A, Chae BT, Zhu ED, Gori F, Demay MB. Phosphate interacts with PTHrP to regulate endochondral bone formation. Endocrinology. 2014;155(10):3750\u20136.","journal-title":"Endocrinology"},{"issue":"4","key":"2590_CR30","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1074\/jbc.M112.410043","volume":"288","author":"M Kawai","year":"2013","unstructured":"Kawai M, Kinoshita S, Kimoto A, Hasegawa Y, Miyagawa K, Yamazaki M, et al. FGF23 suppresses chondrocyte proliferation in the presence of soluble \u03b1-Klotho both in vitro and in vivo. J Biol Chem. 2013;288(4):2414\u201327.","journal-title":"J Biol Chem"},{"issue":"2","key":"2590_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3109\/03008207.2012.753879","volume":"54","author":"A Raimann","year":"2013","unstructured":"Raimann A, Ertl DA, Helmreich M, Sagmeister S, Egerbacher M, Haeusler G. Fibroblast growth factor 23 and Klotho are present in the growth plate. Connect Tissue Res. 2013;54(2):108\u201317.","journal-title":"Connect Tissue Res"},{"issue":"6","key":"2590_CR32","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1542\/peds.113.6.e593","volume":"113","author":"D Haffner","year":"2004","unstructured":"Haffner D, Nissel R, Wuhl E, Mehls O. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics. 2004;113(6):e593\u20136.","journal-title":"Pediatrics"},{"key":"2590_CR33","doi-asserted-by":"publisher","unstructured":"Yang HM, Mao M, Yang F, Wan C. Recombinant growth hormone therapy for X-linked hypophosphatemia in children. Cochrane Cystic Fibrosis and Genetic Disorders Group, \u00e9diteur. Cochrane Database of Systematic Reviews [Internet]. 24 janv 2005 [cit\u00e9 31 mars 2020]; Disponible sur: https:\/\/doi.org\/10.1002\/14651858.CD004447.pub2","DOI":"10.1002\/14651858.CD004447.pub2"},{"issue":"4","key":"2590_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00467-012-2364-9","volume":"28","author":"F Santos","year":"2013","unstructured":"Santos F, Fuente R, Mejia N, Mantecon L, Gil-Pe\u00f1a H, Ordo\u00f1ez FA. Hypophosphatemia and growth. Pediatr Nephrol. 2013;28(4):595\u2013603.","journal-title":"Pediatr Nephrol"},{"key":"2590_CR35","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1515\/jpem-2019-0438","volume":"33","author":"JI Labarta","year":"2020","unstructured":"Labarta JI. Growth and metabolic effects of long-term recombinant human growth hormone (rhGH) treatment in short children born small for gestational age: GH-RAST study. J Pediatr Endocrinol Metab. 2020;33:923\u201332.","journal-title":"J Pediatr Endocrinol Metab."},{"issue":"5","key":"2590_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1046\/j.1365-2265.1999.00680.x","volume":"50","author":"S Cameron","year":"1999","unstructured":"Cameron S, Daneman K. A trial of growth hormone therapy in well-controlled hypophosphataemic rickets. Clin Endocrinol. 1999;50(5):577\u201382.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2590_CR37","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1210\/jc.2009-2139","volume":"95","author":"P Cohen","year":"2010","unstructured":"Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG, et al. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab. 2010;95(5):2089\u201398.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2590_CR38","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1210\/jc.2007-0204","volume":"92","author":"P Cohen","year":"2007","unstructured":"Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007;92(7):2480\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"2590_CR39","unstructured":"The WHO. The WHO child growth standards. Available at http:\/\/www.who.int\/childgrowth\/standards\/en\/."},{"issue":"1","key":"2590_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1687-9856-2015-1","volume":"2015","author":"JL Ross","year":"2015","unstructured":"Ross JL, Lee PA, Gut R, Germak J. Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER program. Int J Pediatr Endocrinol. 2015;2015(1):1.","journal-title":"Int J Pediatr Endocrinol"},{"issue":"1","key":"2590_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12887-020-02034-8","volume":"20","author":"D Wu","year":"2020","unstructured":"Wu D, Chen R, Chen S, Liu G, Chen L, Yang Y, et al. Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty. BMC Pediatr. 2020;20(1):138.","journal-title":"BMC Pediatr"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02590-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T12:08:28Z","timestamp":1671624508000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02590-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2590"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02590-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"4 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the French National Data Processing and Liberties Commission (CNIL number 1920371v0), and in accordance with the Jard\u00e9 law in France, the need for written consent was waived. After patients and\/or their parents had been informed orally about the study, oral consent was obtained from parents and oral assent from minors (as appropriate). It was clarified that they had the right to withdraw from the study at any time by completing a form available through .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"JA nothing to disclose; VVZ reports the speaker\u2019s fees and the travel grants from Kyowa Kirin, Novonordisk, unrelated to this research; ASL nothing to disclose; JPS nothing to disclose; BM nothing to disclose; CB nothing to disclose; CC nothing to disclose; AR reports the speaker\u2019s fees and the travel grants from Kyowa Kirin; AL reports e research grant from Kyowa Kirin, honoraria and consulting fees from Pfizer, Novonordisk, Merck Serono and Sandoz, unrelated to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"444"}}